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The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia 
and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of 
the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed 
in t(4;11)+ B-cell acute lymphoblastic leukemia patients, but the reciprocal fusion A4M is expressed in only 
half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic 
differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic 
differentiation models to study whether the A4M fusion cooperates with MA4 during early human 
hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-
endothelial precursors, both endothelial- and hemogenic-primed. Double fusion-expressing hemato-
endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-
committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. 
Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions 
by RNA-seq and H3K79me3 ChIP-seq, respectively, confirmed a hematopoietic/endothelial cell 
differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, ChIP-seq 
analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A 
cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish 










The mixed-lineage leukemia (MLL) gene encodes for an H3K4 histone methyltransferase important in 
hematopoietic development1. The human MLL gene is frequently rearranged in acute leukemia and typically 
confers a dismal outcome2, 3. Of particular interest is the translocation t(4;11)(q21;q23), which encodes the 
fusion proteins MLL-AF4 (MA4) and AF4-MLL (A4M), and is associated with infant B-cell acute lymphoblastic 
leukemia (B-ALL). This t(4;11)+ infant leukemia is characterized by a very brief latency, raising the question 
of how it evolves so quickly4. Moreover, the exceptionally high concordance rate of t(4;11)+ B-ALL in 
monozygotic twin infants5, 6 suggests that all the necessary (epi)genetic events required for leukemogenesis 
are accomplished prenatally, during embryonic/fetal hematopoietic development7. However, our 
understanding of t(4;11)-mediated developmental effects is limited, at least in part, due to the variety of 
phenotypes and long latency observed in currently available t(4;11) mouse models2, 8-17. These different 
phenotypes likely result from targeting a cell in the wrong developmental stage, or not addressing the impact 
of secondary hits, leaving open questions about the developmental impact of the t(4;11) translocation during 
early human development.  
 
The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative 
translocated chromosomes remains obscure in cancer. The MA4 fusion is always expressed in t(4;11)+B-
ALL patients, whereas the reciprocal fusion A4M is expressed in only half of the patients18-20. Importantly, 
t(4;11)+ cell lines display addiction to MA4 but not to A4M21, 22, and although A4M was not sufficient to initiate 
leukemia in cord blood-derived CD34+ cells23, it was nevertheless capable of initiating B-ALL in mice without 
the requirement of MA4, indicating that it contributes to t(4;11)-driven leukemogenesis11, 24, 25. Strikingly, a 
very recent clinical study have unraveled an independent prognostic value for MA4 expression in t(4;11)+ 
infant B-ALL, thus adding a new piece to the puzzle19. Thus, the developmental/pathogenic contribution of 
the t(4;11)-resulting reciprocal fusion A4M remains enigmatic. 
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Human embryonic stem cells (hESCs) represent a powerful tool for modeling different developmental aspects 
of human disease that cannot otherwise be addressed by patient sample analyses or mouse models7, 26, 27. 
Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, modeling 
hematopoietic differentiation in hESCs may represent a promising in vitro approach to study the onset of 
hematopoiesis and the mechanisms underlying early human hematopoietic development7. During hESC 
differentiation, a primitive population of CD45- hemato-endothelial precursors (HEPs) arises and further 
differentiates into CD45+ hematopoietic and mature endothelial cells28-30. Beyond their pathogenic role in 
acute leukemias, the MLL gene has also been implicated in endothelial cell maturation31, and endothelial 
dysfunction was recently linked to disease outcomes in childhood leukemias32. We previously reported that 
MA4 favors the emergence of endothelial-primed HEPs but not hemogenic HEPs from hESCs10. Here, we 
took advantage of well-established hESC-based differentiation systems to study whether the A4M fusion 
cooperates with MA4 during early human hematopoietic and endothelial development. We report a functional 
and molecular cooperation between MA4 and A4M fusions, which results in an enhanced hemato-endothelial 














Vector construction and lentiviral transduction 
The cDNAs for MA4 and A4M were subcloned into the pRRL-EF1α-PGK-NEO vector11, 16. Both fusions have 
been described previously (FigS1A)11, 23. We used the following lentivectors containing either neomycin or 
dTo for cell selection: pRRL-EF1α-PGK-NEO (empty vector;EV), pRRL-EF1α-MA4-PGK-NEO (MA4) and 
pRRL-EF1α-A4M-PGK-dTo (A4M). VSV-G-pseudotyped lentiviral particles were generated in 293T cells 
using standard transfection protocols and concentrated by ultracentrifugation33. hESCs were infected 
overnight with concentrated EV or MA4 lentivirus plus 8 μg/ml polybrene. Viral supernatants were washed 
away the next day, and EV- and MA4-transduced hESCs were then selected with G418 (50-100g/ml) for 
three weeks. For dual transduction of MA4 and A4M fusions, G418-resistant MA4-expressing hESCs were 
infected with A4M-expressing viruses. EV/G418-selected hESCs were also transduced with A4M alone. 
Transgene expression was confirmed for all the genotypes (Fig1). 
 
Human ESC culture and characterization of transgenic human ESC lines 
hESCs (AND1 line) were maintained undifferentiated on a layer of irradiated-hMSCs (iMSC) in complete KO-
DMEM medium containing 20% knockout serum replacement and 8 ng/mL basic fibroblast growth factor 
(bFGF)34, 35. The medium was changed daily, and cells were passaged weekly by dissociation with 1:1 
collagenase IV:Dispase. Cultures were visualized daily by phase contrast microscopy. Approval for hESC 
work was obtained from the Spanish National Embryo Ethical Committee. Pluripotency of transgenic hESCs 
was characterized by flow cytometry using antibodies against SSEA-3, SSEA-4 TRA-1-60 and TRA-1-81 (BD 
Biosciences)36. Expression of the pluripotency-associated transcription factors OCT4, NANOG, SOX2, 
CRIPTO, and DNMT3B as well as transgene expression (MA4 and A4M) were analyzed by qRT-PCR. 
TableS1 shows the primers and PCR conditions used23, 37, 38. 
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Hematopoietic differentiation from human ESCs by embryoid body formation. 
Undifferentiated hESCs were treated with collagenase IV:Dispase for 1 hr at 37ºC. For embryoid body (EB) 
formation, cells were transferred to low-attachment plates and incubated overnight in differentiation medium 
(DM; KO-DMEM supplemented with 20% FBS, 1% nonessential amino acids, 1 mmol/L L-glutamine, and 0.1 
mmol/L -mercaptoethanol). The medium was changed next day to the same DM supplemented with the 
following hematopoietic cytokines: 300 ng/mL stem cell factor (SCF), 300 ng/mL Flt3L, 10 ng/mL interleukin 
(IL)-3, 10 ng/mL IL-6, 50 ng/mL granulocyte-colony stimulating factor (G-CSF) and 25 ng/mL bone 
morphogenetic protein 4 (BMP-4) (all from R&D)9, 29, 39-41. EBs were dissociated at different time points during 
development using collagenase B and enzyme-free Cell Dissociation Buffer (Invitrogen). Dissociated cells 
were stained with anti-CD34-PE, anti-CD31-FITC, anti-CD45-APC or anti-CD34-PE-Cy7, CD31-BV510, anti-
Glycophorin A, anti-CD43-FITC, anti-CD45-APC antibodies (all from BD Biosciences) and 7-actinomycin D, 
and analyzed using a FACS Canto flow cytometer9, 29, 39-41. Colony-forming unit (CFU) assays were performed 
at day 10 and 15 of EB differentiation by plating 60x104 EB cells onto serum-free methylcellulose H4435 
(Stem Cell Technologies). Colonies were scored after 12 days9, 29, 42-44. 
 
Cell cycle and apoptosis analysis  
For cell cycle analysis of hESC-derived HEPs and CD45+ cells, day 15 EBs were dissociated and harvested 
cells were fixed overnight in 70% ice-cold ethanol. Cells were then washed in PBS and incubated with anti-
CD31-FITC, anti-CD34-PE-Cy7 and anti-CD45-APC antibodies for 15 min. Cells were then suspended in 
propidium iodide-containing buffer and acquired-analysed on a FACS Canto-II using Modfit LT4.0 software, 
discriminating between quiescent cells (G0/G1), cycling cells (S-phase) and G2/M cells45, 46. Apoptosis was 




Human ESC-OP9 co-cultures 
hESC-OP9 co-cultures were performed as described47, 48. OP9 stroma was prepared by plating OP9 cells in 
gelatin-coated dishes, and allowing them to overgrow as a monolayer. hESCs were prepared as a suspension 
of small aggregates using collagenase IV:Dispase. One-tenth of this suspension was plated on top of the 8-
day overgrown OP9 stroma. Media was replaced on the next day and one-half volume media changes were 
performed every other day thereafter. Hematopoietic differentiation was assessed by flow cytometry at day 
9 of co-culture. Accordingly, hESC-OP9 co-cultures were treated with collagenase IV/TrypLE and cells were 
dissociated and filtered through a 70-µm strainer. Cell suspensions were stained with anti-mouse CD29-
FITC and anti-human CD34-PE and CD45-APC antibodies. The proportion of HEPs (CD34+CD31+CD45-), 
and total blood cells (CD45+) was analyzed within the CD29- human ESC-derived cell population. Hemogenic 
and endothelial HEPs were distinguished based on CD34 and CD43 expression40. 
 
Culture of FACS-isolated HEPs in MS5 stroma or liquid culture 
Day 9 human hESC-OP9 co-cultures were dissociated as above and both CD45+ cells and HEPs were 
analyzed. FACS-purified HEPs (CD29-CD34+CD31+CD45-) were plated onto MS5 stroma or in liquid culture 
for 30 or 16 days, respectively, in DM with hematopoietic cytokines (50 ng/mL SCF, 50 ng/mL Flt3L, 10 ng/mL 
IL-3,20 ng/mL IL-7). The medium was changed every 7 days, and the emergence of CD45+ hematopoietic 
cells was analyzed by FACS. 
 
Endothelial differentiation of HEPs  
HEPS (2×104) from day 9 human hESC-OP9 co-cultures were seeded onto 0.1% gelatin-coated plates in 
complete EGM-2 medium with microvasculature supplements (Lonza) for 7 days. Cells were then fixed, 
permeabilized and stained with rabbit anti-human VE-cadherin (Cayman), mouse anti-human eNOS (BD 
Biosciences), and mouse anti-human vWF (DAKO) followed by Alexa488-conjugated anti-rabbit or Cy3-
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conjugated anti-mouse (Jakson Immunoresearch) antibodies. Nuclei were counterstained with DAPI. Images 
were obtained using an inverted fluorescence microscope. Day 7 differentiating cells were trypsinized and 
cell suspensions were stained with anti-human CD31-FITC and CD144-PerCP-Cy5.5 antibodies. 
 
Mouse transplantation and analysis of hematopoietic-endothelial engraftment  
NOD/LtSz-scid IL-2Rγ−/− (NSG) mice were housed under sterile conditions. The Animal Care Committee 
approved all mouse protocols. Briefly, cord bood-derived CD34+ HSPCs (3×104 cells) or cells from day 15 
EBs (5×105 cells) were intra-bone marrow (BM)-transplanted as described49. Animal health was monitored 
throughout the entire experiment. Mice were killed 10 weeks after transplantation and cell suspensions were 
analyzed by FACS for human chimerism using anti-HLA-ABC-FITC, anti-CD31-PE, CD144-PerCP-Cy5.5, 
and anti-CD45-APC antibodies. 
 
Statistical analysis 
All data are expressed as mean±SEM. Statistical comparisons were performed using the GraphPad Prism 
software with the nonparametric Mann-Whitney test, two-tailed P-value (95% confidence interval). Statistical 
significance was defined as a p-value<0.05. 
 






Co-expression of A4M and MA4 does not hijack pluripotency 
We showed very recently that only 45% of t(4;11)+ B-ALL patients express the reciprocal fusion A4M, 
whereas MA4 is consistently expressed in all t(4;11)+ B-ALL patients (Fig1A)18-20. Here, we generated 
transgenic hESC lines expressing “MA4 alone”, “A4M alone” or MA4+A4M (double fusion, Fig1B, S1B). EV 
(control)- and MA4-hESCs were established by G418 selection9. G418-resistant EV- or MA4-expressing 
hESCs were then transduced with A4M/dTo-expressing lentiviruses and >90% transduction efficiency was 
achieved. Transgenic hESC lines were maintained for >50 passages and retained human ESC-like 
morphology (Fig1B, left), transgene expression (Fig1B, right), and expression of pluripotency-associated 
transcription factors (Fig1C) and surface markers (Fig1D). All hESC genotypes formed teratomas in NSG 
mice (data not shown)9, 50. Thus, (co-)expression of A4M and/or MA4 is compatible with hESC pluripotency. 
 
A4M and MA4 co-operate to promote HEPs emergence and enhance blood production 
Hematopoietic differentiation was assessed using two distinct and well-established differentiation systems: 
EB formation43, 47 (Fig2) and OP9 co-culture47, 48 (Fig3). During differentiation, a population of primitive HEPs 
arises, which is responsible for further hematopoietic and endothelial commitment10, 30 (Fig2A,3A). We 
investigated whether co-expression of A4M and MA4 impacts hESC-derived hematopoiesis by analyzing the 
emergence of HEPs during EB development in hESCs individually expressing the single fusions or the double 
fusion. We observed a pronounced (~5-10-fold; p<0.05) increase in HEPs at day 7 and 10 of development in 
EBs expressing the double A4M and MA4 fusion over single fusions (Fig2B, upper-left panel). We next 
assessed whether co-expression of A4M and MA4 influences subsequent hematopoietic commitment of 
HEPs. The kinetics of emergence and output of both total CD45+ hematopoietic cells and CD45+CD34+ 
hematopoietic progenitors was faster (EB day 10) from double fusion-expressing hESCs than from equivalent 
single fusion-expressing cells, achieving a 2-3-fold higher hematopoietic output by day 15 of EB development 
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(Fig2B). Furthermore, double fusion-expressing HEPs massively accelerated (EB day10) the emergence of 
clonogenic hematopoietic progenitors as compared to single fusion-expressing HEPs (Fig2B, bottom-right 
panel). According to our previous work, if the kinetics of hEB differentiation are extended allowing for a 
continuum HEP-to-blood transition, MA4-expressing hEBs display an enhanced HEP production coupled to 
an impaired blood output (EB day 20, Fig S2A) and clonogenic potential (EB day 15, Fig 2B). We confirmed 
stable expression of ectopic MA4 and A4M upon EB differentiation, supporting the link between genotype 
and phenotype (Fig2C).  
 
We also investigated hematopoietic differentiation using the OP9 differentiation system (Fig3A,B), and by 
plating FACS-sorted HEPs in either hematopoietic liquid culture (Fig3C) or onto MS5 feeders (Fig3D). After 
10 days on OP9 stroma, double fusion-expressing hESCs yielded a 10-fold higher number of CD45+ 
hematopoietic cells than did single fusion-expressing hESCs (Fig3B). Moreover, when HEPs were FACS-
sorted from day 9 OP9 co-cultures and allowed to differentiate into CD45+ blood cells, the yield of CD45+ 
cells was up to 60-fold higher in double fusion-expressing HEPs than in single fusion-expressing HEPs. 
(Fig3C,D). Encouraged by these results, we next investigated whether ectopic expression of both A4M and 
MA4 confers in vivo engraftment capacity to hESC-derived hematopoietic derivatives. To do this, we 
transplanted 5×105 hESC hematopoietic derivatives from each genotype into myeloablated NSG mice4, 43, 47, 
finding that, despite regulating hematopoietic development in vitro, double fusion-expression did not confer 
in vivo engraftment to hESC hematopoietic derivatives (Fig2D).   
 
The increased hematopoietic output of double fusion-expressing hESCs might be the consequence of 
transgene-mediated proliferation/survival of the emerging HEPs or CD45+ cells. To address this, we 
analyzed cell cycle distribution (FigS2B) and apoptosis (FigS2C) within both HEPs and the CD45+ cell 
population. No differences in the proportion of either cycling HEPs or CD45+ cells were detected between 
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genotypes (25–36% for HEPs and 35–41% for CD45+ cells; FigS2B). Apoptotic levels were similarly low 
between the different genotypes of HEPs (6–8%) and CD45+ cells (5–7%) (FigS2C). Collectively, these 
results show that A4M cooperates with MA4 to induce HEP specification and blood commitment, without 
hijacking proliferation or survival of HEPs.  
 
A4M and MA4 co-operate to enhance endothelial cell fate from HEPs 
We next addressed the developmental impact of A4M in endothelial maturation from HEPs10, 47. We 
hypothesized that co-expression of A4M and MA4 in HEPs may (i) concomitantly promote subsequent 
endothelial and hematopoietic commitment or (ii) skew the hemato-endothelial commitment in favor of 
hematopoiesis. To test this, we analyzed the ability of HEPs to differentiate into mature endothelial cells. 
OP9-hESC co-cultures were dissociated on day 9 of development and HEPs were FACS-sorted and cultured 
for a week in endothelial-promoting conditions (Fig4A). The expression of the mature endothelial markers 
VE-cadherin (CD144), vWF, eNOS and CD31 was then analyzed. Irrespective of the genotype, HEPs 
cultured in endothelial conditions attached, became spindle-shaped, and formed VE-Cad+ endothelial-like 
structures co-expressing eNOS, vWF and CD31 (Fig4B,C, top panel). However, double fusion-expressing 
HEPs were more prone to differentiate into mature endothelial cells than single fusion-expressing HEPs. 
Accordingly, they yielded a 20-fold higher number of VE-Cad+ endothelial-like structures (Fig4C, top panel) 
and CD144+CD31+ endothelial cells (Fig4C, bottom panel). Interestingly, endothelial cells 
(HLA.ABC+CD31+CD34+CD144+CD45-CD43-) were found in the BM of mice transplanted with double fusion-
expressing hESC blood derivatives at levels ~4-fold higher than in mice transplanted with single fusion-
expressing cells (Fig4D). 
 
Within CD34+CD31+CD45- HEPs, two subpopulations of phenotypically and functionally distinct HEPs can be 
distinguished based on the expression of CD34 and CD43: hemogenic HEPs (CD34low/+CD43+CD45-) and 
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endothelial HEPs (CD34++CD43-CD45-) (Fig5A)40, 48, 51. We thus analyzed the contribution of both HEP 
populations to the superior hematopoietic and endothelial differentiation observed in double fusion-
expressing HEPs. Co-expression of A4M and MA4, but not single fusions, robustly enhanced the emergence 
of both endothelial and hemogenic HEPs (Fig5B,C). The identity of hemogenic and endothelial HEPs was 
confirmed by the specific expression of early hematopoietic and endothelial master genes (Fig5D). Thus, 
A4M cooperates with MA4 to promote hematopoietic and endothelial cell fate. 
 
Genome-wide transcriptomic and H3K79 methylation profiles support the developmental cooperation 
between A4M and MA4 
To identify patterns of gene expression that might molecularly explain the functional co-operation between 
A4M and MA4 in hematopoietic specification, we performed RNA-seq analysis on FACS-purified EV-, MA4, 
A4M- and double fusion-expressing HEPs from day 15 hEBs. Fig6A shows a heatmap representation of the 
hierarchical clustering of the 335 genes differentially expressed between the four genotypes (TableS2). 
There is a clear transcriptomic transition towards a hematopoietic/endothelial gene signature from EV-HEPs 
to double-fusion-expressing HEPs. Single fusion-expressing HEPs clustered interspersed between EV and 
double-fusion HEPs. The biological functions affected by genes differentially expressed in MA4-, A4M- and 
double fusion-expressing HEPs relative to EV were classified by IPA software47, 52 and among the top 
significant enriched functional categories were “hematological system development and function”, “cancer” 
and “hematological disease” (Fig6B). Statistical (-log(p-value)) power shows distant effects of MA4 and A4M; 
however, co-expression of both fusions seems to establish a molecular balance/developmental cooperation 
in promoting blood-endothelial specification from hPSCs. Strikingly, biofunctions specifically associated to 
hematological lymphoid malignancies (not with non-hematological cancer) were predicted to be activated 
(positive z-score) exclusively in double fusion-expressing HEPs, further suggesting a molecular cooperation 
between MA4 and A4M in development and infant leukemia. (Fig6C). 
13 
 
The C-terminal-partners of MLL fusions normally interact with the histone methyltransferase DOT1L, which 
is the sole histone methyltransferase catalyzing histone 3 lysine 79 (H3K79) methylation, a chromatin 
modification widely associated with the dysregulated expression of HOX-A cluster genes in MLL leukemias 
13, 53. We thus performed genome-wide ChIP-seq analysis of the H3K79 trimethylation (H3K79me3) profiles 
in control, MA4-, A4M- and double fusion-expressing hESC-derived blood derivatives (Fig7,S3A, TableS3). 
In line with the RNA-seq data, functional analysis of the differential H3K79me3 peaks specific for double 
fusion-expressing cells revealed significant GO functional categories associated with ”definitive 
hematopoiesis”, “myeloid and erythroid differentiation/homeostasis” and “endothelial cell development” 
(Fig7A,S3B). This further supports the developmental co-operation between A4M and MA4 in promoting 
hemato-endothelial specification. 
 
Finally, we analysed the H3K79me3 profiles at genomic loci of the classical MLL target genes reported by 
Guenther et al54. Non-HOX-A classical MLL targets such as RUNX1, LMO2, ADMA10, and KDM6A showed 
a slight although non-significant, enrichment of H3K79me3 in MA4-expressing hESCs, validating our ChIP-
seq approach (Fig7B). However, enrichment of H3K79me3 in HOX-A cluster genes was observed 
exclusively in A4M-expressing cells although it was statistically significant only in double fusion-expressing 
differentiating hESCs (FDR<0.1) (Fig7C). As such, HOX-A genes were up-regulated in double-fusion-
expressing hematopoietic clonogenic progenitors (FigS3C). No differential enrichment of the repressive 
H3K4me2/3 mark was observed in either HOX-A or non-HOX genes in double fusion-expressing cells 
(FigS4). Collectively, these data suggest that the deregulated expression of HOX-A genes in MLL leukemias 
may be imposed by the reciprocal A4M fusion through a H3K79 methyltransferase activity. In support of this, 
a recent RNA-seq study performed in 42 infants with t(4;11)+ B-ALL enrolled in the Interfant treatment 
protocol, reveal that 45% of t(4;11)+ patients express the A4M fusion, and that HOX-A cluster genes are 
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exclusively expressed in this AF4-MLL-expressing subgroup of t(4;11)+ patients, who in fact display a 




From an etiological and pathogenesis standpoint, infant cancer is distinct to adult cancer and should be 
studied as a developmental disease4, 7, 16. A biologically and clinically intriguing infant cancer is the t(4;11)+ 
B-ALL, which is associated with a dismal outcome4, 21, 23. Evidence in support of its prenatal origin comes 
from studies in monozygotic twins and archived blood spots, providing compelling evidence of a single 
prenatal cell as the origin for t(4;11)5, and also from recent genome-wide studies demonstrating that this 
infant leukemia has one of the lowest frequencies of somatic mutations of any sequenced cancer55. The 
stable genome of these patients suggests that in infant developmental cancer, one “big-hit” might be sufficient 
for overt disease, supporting a key contribution of the prenatal cell-of-origin during a critical developmental 
window of stem cell vulnerability in leukemogenesis. However, despite its aggressiveness and short latency, 
our current understanding about its etiology, pathogenesis and cellular origin is still limited2, 4, 14, 16, 52. 
Importantly, a recently developed xenograft model which represents the most bona fide model for t(4;11)+ B-
ALL so far, has revealed the instructive role of MLL-Af4 in cord blood-derived CD34+ cells14. 
 
Studies using primary cells from t(4;11)+ B-ALL patients are incapable of addressing the developmental 
genesis of the hematopoietic system. Recent data suggest that fetal liver lymphoid-primed multipotent 
progenitor may provide the developmental prerequisites for the initiation of t(4;11)+/MLL-AF4 infant 
leukemia56. Because leukemogenesis manifests as a blockage or altered cell differentiation, the 
hematopoietic differentiation of hESCs may represent a promising in vitro model to study the onset of 
hematopoiesis and the earliest events leading to the specification of the hematopoietic cells36. Previous 
studies have addressed the oncogenic role of leukemic fusion genes in hESC-derived hematopoiesis57,58, 59. 
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We previously explored the developmental impact of the pre-natal fusion MA4 in hESC hemato-endothelial 
development10, and found that MA4 expression promotes the emergence of endothelial-primed HEPs and 
further endothelial commitment, but hijacks the specification of hemogenic-primed HEPs, impairing 
hematopoietic output10. 
 
The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative 
translocated chromosomes remains obscure in cancer18, 60. The MA4 fusion is always expressed in t(4;11)+B-
ALL patients, whereas the reciprocal fusion A4M is expressed in only 45-50% of the patients18, 60,19, 20. Here, 
we took advantage of well-established hESC-based differentiation systems to study whether the A4M fusion 
cooperates with MA4 during early human hematopoietic and endothelial development. Co-expression of A4M 
and MA4 strongly promoted the emergence of HEPs, both endothelial-primed and hemogenic-primed. 
Moreover, the double fusion-expressing HEPs specified into significantly higher numbers of both 
hematopoietic and endothelial cells, irrespective of the in vitro differentiation protocol used and without 
affecting survival or proliferation, indicating a functional (developmental) co-operation between MA4 and A4M 
fusions during human hematopoietic development. This notion was confirmed by genome-wide 
transcriptomic analysis of differentiating HEPs. These developmental biology studies support previous 
evidence suggesting that A4M contributes to the pathobiology of t(4;11)+ B-ALL. Accordingly, Bursen11 
reported that A4M-transduced murine hematopoietic stem cells (HSCs) developed pro-B-ALL, whereas co-
transduction with MA4 and A4M resulted in mixed lineage leukemia. Moreover, studies from Milne’s 
laboratory demonstrated that RUNX1 is directly activated by MA4 and the RUNX1 protein interacts with the 
A4M protein, suggesting a mechanism of co-operation between the two fusion genes at the molecular level25. 
 
In the embryo, definitive hematopoiesis cannot occur in the absence of endothelial cell development. 
Definitive HSCs in both mouse and human emerge from the hemogenic endothelium by a process known as 
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endothelial-to-hematopoietic transition61. Hematopoietic differentiation of hESCs occurs through the 
generation of HEPs, from which then originate both endothelial and hematopoietic cells. Here, co-expression 
of A4M and MA4 in HEPs concomitantly promoted endothelial and hematopoietic commitment rather than 
skewing the hemato-endothelial commitment in favor of one lineage over the other. This finding is important 
because beyond their pathogenic role in acute leukemias, the MLL gene is implicated in endothelial cell 
maturation, and endothelial dysfunction was recently linked to disease outcome in childhood leukemias31, 32. 
Furthermore, other leukemia fusion oncogenes as well as lymphoma-specific genetic aberrations have been 
found in endothelial cells from chronic myeloid leukemia and B-cell lymphoma patients10, 43, 44, suggesting 
that endothelial cells may be part of the neoplastic clone. Also, BM-derived mesenchymal stem cells (BM-
MSCs) from infant t(4;11)+ B-cell ALL were recently found to harbor and express the t(4;11) translocation33. 
The existence of a common embryonic precursor for MSCs and endothelial cells has been recently 
demonstrated by hESC-directed differentiation10, 45. The finding of such a common embryonic precursor, and 
the presence of t(4;11) in both leukemic blasts and BM-MSCs of infant patients, suggests that the t(4;11) 
translocation arises and has a developmental impact on early pre-hematopoietic precursors. As a technical 
caveat, it is important to emphasize that MA4 and A4M were sequentially transduced to allow for antibiotic 
selection and homogeneously-transduced hESC cultures. However, in double-fusion-expressing 
differentiating blood cells, MA4 was never individually expressed in the absence of A4M. When hematopoietic 
differentiation of hESCs was induced by EB formation both fusions were readily co-expressed, ruling out a 




Mechanistically, a putative function of A4M is to activate chromatin, rendering a chromatin landscape similar 
to that during stem cell development. It is currently unknown how A4M is able to reprogram chromatin, but it 
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does contain the SET domain disrupted from its "specification domain", the N-terminal portion of MLL, which 
binds to MEN1 and LEDGF, shaping the gene targeting module of the MLL gene. When A4M is expressed, 
the N-terminal portion is substituted by the AF4 N-terminus, which is the crucial domain (AF4N) that binds to 
and strongly activates RNA polymerase II (RNAP II) for transcriptional elongation. Overexpression of either 
AF4, AF4N or the fusion protein A4M induces robust RNAP II-dependent gene transcription by overwriting 
the elongation control process in a dominant fashion62-64. Since gene transcription per se and in particular 
“sterile” transcription is a powerful mechanism for chromatin activation, A4M could potentiate MA4 to skew 
normal and leukemic hematopoietic cell fate decisions. This also explains why MA4 has a more prominent 
role in the disease than the reciprocal A4M. If A4M functioned to initiate this process only by itself, then it 
would become obsolete after fulfilling the "chromatin opening job". However, transcription factors like MA4, 
RUNX1 or others then establish the transcriptional program leading to leukemogenesis. This is reflected in 
the enhanced hematopoietic potential of double fusion-expressing hESCs and the enriched H3K79me3 
activation mark in HOX-A cluster genes exclusively when MA4 and A4M are co-expressed. Thus, A4M 
prepares other transcription factors to become oncoproteins. 
 
Molecularly, C-terminal-partners of MLL fusions (AF4, AF9, ENL) interact with DOT1L, which is the sole 
histone methyltransferase catalyzing H3K79 methylation, a chromatin modification widely associated with the 
dysregulated expression of HOX-A gene cluster in MLL-rearranged leukemias13, 53. Here, ChIP-seq analysis 
of differentially enriched H3K79me3 genomic regions confirmed a hematopoietic/endothelial cell 
differentiation signature in double fusion-expressing HEPs, and revealed a significant enrichment of H3K79 
methylated regions specifically associated with HOX-A cluster MLL target genes (but not to non-HOX-A MLL 
targets) in double fusion-expressing differentiating hematopoietic cells. This is in line with the recently found 
significant positive correlation between the upregulation of the HOX-A gene cluster and the expression of 
A4M in primary t(4;11)+ infant B-cell ALL samples, and with previous studies identifying that approximately 
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one-half of t(4;11)+ patients do not have an activated HOX-A signature20, 65, 66. This may explain why MA4 
failed recently to bind to HOX-A genes to regulate HOXA gene expression14. Collectively, MA4 and A4M 
might cooperate through a complex molecular interaction to control HOX-A gene regulation25. In sum, we 
describe a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic 
development, and demonstrate how hESC-based hematopoietic differentiation represents a promising 
system to explore the developmental impact of the chimeric proteins resulting from chromosomal 
translocations, which remains obscure in human leukemia. 
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Figure 1. Characterization of transgenic human ESCs expressing the reciprocal fusion A4M together 
with MA4. (A) RNA-seq and qRT-PCR validation revealed that ~45% (11/25) of the patients with t(4;11)+ B-
ALL do not express the reciprocal fusion A4M18. (B) Left, Phase-contrast morphology of representative 
colonies from each transgenic hESC line. Right, RT-PCR confirming expression of both fusions in 
undifferentiated hESCs. (C) qRT-PCR expression of the pluripotency genes OCT4, SOX2, NANOG, 
CRIPTO, and DNMT3B. (D) Representative FACS data confirming expression of the pluripotency surface 
makers SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. 
 
Figure 2. A4M cooperates with MA4 to accelerate human ESC/EB specification towards HEPs and 
subsequent hematopoietic differentiation. (A) Schematic of EB hematopoietic differentiation of hESCs 
and end-point analyses. (B) Upper left, specification into HEPs (CD31+CD34+CD45-) is accelerated in double 
fusion-expressing hESCs. Subsequent differentiation of HEPs into hematopoietic progenitors (upper right) 
and mature CD45+ blood cells (bottom left) is enhanced in double fusion-expressing HEPs. Bottom right, CFU 
read-out and scoring (pie charts) confirming an accelerated and enhanced hematopoietic progenitor potential 
from double fusion-expressing blood derivatives. (C) RT-PCR confirming stable expression of MA4 and A4M 
upon EB differentiation. (D) Neither MA4- nor double fusion-expressing blood derivatives display in vivo 
hematopoietic engraftment potential in irradiated NSG mice. Data are presented as mean±SEM from at least 
three independent experiments. *p<0.05. 
 
Figure 3. Co-expression of MA4 and A4M enhances hematopoietic differentiation of human ESCs in 
OP9 co-culture. (A) Experimental design of OP9-based hESC differentiation towards HEPs and further 
hematopoietic commitment of HEPs maintained in either liquid culture for 16 days or in MS5 co-culture for 
30 days. (B) Frequency of total CD45+ blood cells after 9 days in OP9 co-culture. (C,D) CD45-CD31+CD34+ 
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HEPs were FACS-purified at day 9 of OP9 co-culture and allowed to differentiate into CD45+ cells in liquid 
culture (C) or in MS5 co-culture (D). Data represent mean±SEM from independent experiments. 
  
Figure 4. Enhanced endothelial cell fate from HEPs co-expressing MA4 and A4M. (A) Scheme of HEPs 
endothelial differentiation and phenotypic characterization. (B) FACS-sorted HEPs from day 9 human ESC-
OP9 co-cultures were cultured in EGM2 medium for 5 days and analyzed by immunofluorescence for VE-
cadherin, eNOS and vWF. (C) Top, Endothelial-like structures were identified and quantified based on VE-
cadherin staining (white dotted-lined areas in B, top panel). Bottom, Frequency of CD45-CD31+CD144+ 
endothelial cells quantified by flow cytometry. (D) In vivo endothelial engraftment potential 
(HLA.ABC+CD31+CD144+CD45-) analyzed in bone marrow of NSG mice 8 weeks after transplantation of 
HEPs. Data presented as mean±SEM from 5 independent experiments. *p<0.05. 
 
Figure 5. Co-expression of MA4 and A4M significantly enhances the emergence of both endothelial 
and hemogenic HEPs. (A) Representative flow cytometry analysis of HEPs with hemogenic (CD45-
CD31+CD43+CD34dim/+) and endothelial (CD45-CD31+CD43-CD34++) potential. (B,C) A4M cooperates with 
MA4 to boost the emergence of both endothelial (B) and hemogenic (C) HEPs. Data presented as 
mean±SEM from 3 independent experiments. (D) Expression of RUNX1c and Ve-Cad in hemogenic and 
endothelial HEPs. * p<0.05 
 
Figure 6: Transcriptional transition towards a hematopoietic/endothelial gene signature in double 
fusion-expressing HEPs.  (A) Heatmap representation of hierarchical clustering of genes differentially 
expressed between EV-, single fusions- and double fusion-expressing HEPs. Each column represents a 
technical replicate from three independent experiments. (B,C) Statistically significant functional categories 
(B) and cancer/leukemia-associated biofunctions (C) identified using IPA on genes differentially expressed 
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in single fusions-, and double fusion-expressing HEPs relative to EV. They are ranked by z-score. Functional 
categories associated with “hematological system development and function” and “cardiovascular system 
development” are shown in bold. All significant biofunctions are associated with blood cell differentiation, 
homeostasis and migration/movement. 
 
Figure 7: H3K79 methylation profiles at genomic loci of MLL targets in MA4-, A4M- and double fusion-
expressing human ESC-derived blood derivatives. (A) GO enrichment of differential H3K79me3 peaks 
specific for double fusion-expressing cells. (B-C) Representative profiles for ChIP-seq using anti-H3K79me3 
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SUPPLEMENTARY LEGENDS AND METHODS 
Chromatin immunoprecipitation Sequencing  
One million day 15 hematopoietic differentiating hEB-derived cells were subjected to Chromatin 
Immunoprecipitation (ChIP) as described 1. Briefly, formaldehyde crosslinked cell extracts were 
sonicated using a Bioruptor (Diagenode) with a 0.5-min interval protocol to obtain DNA fragments of 
200–500 bp. The chromatin fraction was divided into three parts and incubated overnight with 2 g of 
anti-H3K4me3, anti-H3K79me3, or anti-H3 antibodies (Abcam) in RIPA buffer, and precipitated with 
protein A/G-Sepharose (Amersham). Cross-linkage of the co-precipitated DNA-protein complexes was 
reversed, and the DNA was sequenced at the CRG-CNAG Genomics Facility. Paired-end 50 bp ChIP-
seq data reads were generated using a HiSeq 2500 Illumina sequencer. Alignment and peak detection 
was performed using the ENCODE (phase-3) histone ChIP-seq pipeline specifications. Reads were 
aligned to the human reference genome (assembly hg19) using BWA2, removing all reads with a quality 
score <30. Peaks were called using MACS23 and whole cell extract samples as background samples. 
Differential analysis of histone mark peaks between experimental groups and the EV control group was 
performed using DiffBind4, with a False Discovery Rate (FDR) cut-off of 0.1. Peaks annotation and 
Gene Ontology (GO) enrichment were analyzed with ChIP-Enrich package in R4, using an FDR 
threshold of 0.1. ChIP-Seq data is deposited and available at Gene Expression Omnibus (GEO, 
accession number GSE111263). 
 
Low-input RNA-seq and bulk RNA-seq on t(4;11)+B-ALL patients 
For low-input RNAseq, 50 HEPs were FACS-purified from day 15 EBs into individual wells of a 96-well 
PCR plate containing lysis buffer (0.2% Triton-X100 and 2.3 U of SUPERase-In RNase Inhibitor; 
Ambion). Three independent replicates (50 cells/replicate) per condition were analyzed. RNA/cDNA 
was obtained and amplified as per the SMARTSEQ2 protocol5,6. Libraries were prepared for 
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sequencing using the Illumina Nextera XT DNA preparation kit. RNA-seq data was generated using a 
50 single-end sequencing protocol. Pooled libraries were sequenced on the Illumina HiSeq 4000 
platform. Reads were mapped to the human genome (Ensembl 81) and the ERCC sequences using 
STAR (version 2.4.2a) with default parameters. HTseq-count7 was used to count the number of reads 
mapped to each gene with -s no (non-strand specific mode). Data were normalized for sequencing 
depth using the size factor from the DESeq2 package (version 1.12.2)8. Low-input RNA-seq data is 
deposited and available at GEO (GSE118947). 
 
Bulk RNA-seq data on t(4;11)+ B-ALL patients was generated on the Illumina HiSeq 2500 platform 
using a 76 paired-end sequencing protocol and aligned to the human reference genome (hg19) using 
Tophat19. A gene was considered differentially expressed in MA4-A4M+ HEPs when it was >2-fold 
regulated (p<0.01) compared with the equivalent gene in EV-HEPs. Analysis of functional categories 
and biofunctions was performed with the genes differentially expressed using Ingenuity Pathway 
Analysis software (Ingenuity Inc., Redwood City, CA). Potential read pairs supporting the expression 
of MA4 and A4M fusion transcripts in patient samples were identified manually and with in-house 
written scripts as pairs in which each read aligned unambiguously to a different gene and which were 
compatible with the genomic breakpoints that were determined at the DNA level in all the samples. 
Additionally, RT-PCR with primers corresponding to AF4 exon3 and MLL exon 12 (exons contained in 
all predicted fusions) was performed in all the samples to confirm the expression of any potential 
isoform of the reciprocal fusion gene. The identity of the isoform was confirmed by capillary sequencing. 
Finally, the expression of each fusion gene was determined by qRT-PCR using primer pairs spanning 
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Figure S1. Coding sequence of the A4M fusion used in this study. (A) The full-length cDNA was 
sequenced-verified. Fusion breakpoint is located in AF4 exon 2 and MLL exon 10. (B) Schematic of 
lentivectors used in this study. 
 
Figure S2. Co-expression of MA4 and A4M promotes specification rather than 
survival/proliferation of HEPs. (A) Day 20 MA4-expressing hEBs display a significant higher HEP 
production coupled to an impaired blood (CD45+ and CD45+CD34+) formation. (B) Left, representative 
FACS analysis of the identification of HEPs and CD45+ hematopoietic cells and their cell-cycle 
distribution. Right, frequency of proliferating (S+G2M phases) CD45+ blood cells and HEPs. (C) Left, 
representative FACS analysis of apoptotic CD45+ hematopoietic cells and HEPs. Right, frequency of 
apoptotic (Annexin V+) HEPs and CD45+ hematopoietic cells for the indicated genotypes. 
 
Figure S3. H3K79me3 ChIP-seq profiles for the different genotypes. (A) Correlation heatmap for 
both H3K79me3 and H3K4me3 using affinity scores based on read counts in consensus peaks 
distinguishes between the four experimental groups. (B) Venn diagrams depicting the number of 
differentially enriched genomic regions for H3K79me3 between experimental groups relative to EV. (C) 
Quantitative expression of the indicated HOX-A genes in CFUs from day 15 EV- and double-fusion-
expressing HEPs. 
 
Figure S4. H3K4me2 profiles at genomic loci of MLL targets identified by Guenther et al. 
Representative profiles for ChIP-seq using an anti-H3K4me3 antibody at genomic sites of HOX-A (A) 
and non-HOX (B) MLL targets in the indicated genotypes of human ESC-differentiating derivatives. 




GAPDH FW GCACCGTCAAGGCTGAGAAC 
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MLL-AF4 Rv GAGCACTTGGAGGTGCAGATG 
AF4-MLL Fw GTTGCAATGCAGCAGAAGCC 
AF4-MLL Rw CAGGGTGATAGCTGTTTCGG 
Downregulated
Table S2: Genes differentially expressed in double fusion-expressing as compared to control (EV) human ESC-derievd HEPs
geneID baseMean log2FoldChange lfcSE stat
ENSG00000112319 EYA4 119,7812612 -7,044862129 0,498747 -14,1251
ENSG00000197956 S100A6 74,70274938 -4,207670299 0,362337 -11,6126
ENSG00000159176 CSRP1 189,5093971 -4,448754354 0,433169 -10,2703
ENSG00000171735 CAMTA1 620,0966312 -2,63097972 0,26318 -9,99688
ENSG00000129595 EPB41L4A 143,8337732 -3,620551338 0,367992 -9,83866
ENSG00000121691 CAT 36,73876494 -4,619144396 0,469468 -9,83911
ENSG00000166770 ZNF667-AS1 26,47276123 -4,671600613 0,476384 -9,80638
ENSG00000053438 NNAT 16,76487505 -3,757812712 0,456726 -8,22772
ENSG00000166575 TMEM135 450,180446 -3,324034043 0,415462 -8,00081
ENSG00000257870 RP11-616L12.1 21,50131485 -4,406254358 0,581565 -7,57654
ENSG00000214872 SMTNL1 29,19194545 -4,020118702 0,547389 -7,34417
ENSG00000126947 ARMCX1 19,10444916 -3,661220371 0,518724 -7,05813
ENSG00000251379 RP11-484O2.1 11,01878906 -4,051707545 0,578618 -7,00239
ENSG00000158716 DUSP23 23,54803256 -3,475578813 0,520465 -6,67784
ENSG00000100644 HIF1A 792,004365 -2,324741527 0,349887 -6,64426
ENSG00000122966 CIT 309,5111002 -2,978040214 0,467302 -6,37283
ENSG00000145681 HAPLN1 1168,660196 -2,488794725 0,394148 -6,31436
ENSG00000123307 NEUROD4 14,76503349 -3,711665311 0,603199 -6,1533
ENSG00000151962 RBM46 8,6172188 -3,652100592 0,593965 -6,14868
ENSG00000164619 BMPER 82,57948722 -3,051493964 0,497697 -6,13122
ENSG00000100290 BIK 43,70310088 -3,317822269 0,541896 -6,12261
ENSG00000050555 LAMC3 20,06173885 -3,21721061 0,531609 -6,05184
ENSG00000167555 ZNF528 15,96797568 -3,401966116 0,57936 -5,87194
ENSG00000149179 C11orf49 373,9107859 -2,410856438 0,411459 -5,85929
ENSG00000137871 ZNF280D 37,3536919 -2,381859852 0,415608 -5,73103
ENSG00000165118 C9orf64 8,084483374 -3,283794749 0,596166 -5,50819
ENSG00000162654 GBP4 82,52014498 -2,47923141 0,458077 -5,41226
ENSG00000076716 GPC4 7,134763765 -3,24223284 0,608348 -5,32957
ENSG00000171476 HOPX 162,0285124 -2,521224355 0,474735 -5,3108
ENSG00000245680 ZNF585B 6,288623057 -3,047314734 0,578532 -5,26732
ENSG00000249252 RP11-665G4.1 10,94518525 -2,963291554 0,582687 -5,08556
ENSG00000142748 FCN3 240,9954012 -2,670085804 0,531573 -5,02299
ENSG00000143614 GATAD2B 90,16811689 -2,123176462 0,42897 -4,94947
ENSG00000185507 IRF7 11,90717047 -2,442768243 0,493898 -4,9459
ENSG00000134817 APLNR 237,009581 -2,180931226 0,442427 -4,92947
ENSG00000125170 DOK4 69,15447671 -1,872722463 0,380282 -4,92456
ENSG00000138315 OIT3 123,6956759 -2,82171733 0,579118 -4,87244
ENSG00000125775 SDCBP2 9,950851737 -2,868043853 0,589784 -4,86288
ENSG00000126709 IFI6 157,1396901 -2,135200905 0,44302 -4,81965
ENSG00000137942 FNBP1L 238,2318442 -1,143914856 0,240099 -4,76435
ENSG00000176728 TTTY14 7,465857067 -2,871826685 0,606999 -4,73119
ENSG00000118515 SGK1 94,59572992 -2,551626347 0,541541 -4,71178
ENSG00000108798 ABI3 32,92496542 -2,143701535 0,456145 -4,6996
ENSG00000008283 CYB561 12,17136654 -2,271524984 0,486907 -4,66522
ENSG00000188778 ADRB3 8,60506653 -2,566915557 0,554624 -4,62821
ENSG00000266472 MRPS21 256,7992655 -1,032266153 0,224316 -4,60184
ENSG00000253929 CASC21 10,99630532 -2,865101044 0,622643 -4,60151
ENSG00000113790 EHHADH 6,601260431 -2,771625162 0,620618 -4,46591
ENSG00000225792 AC004540.4 33,51932827 -2,490684309 0,564859 -4,40939
ENSG00000253438 PCAT1 26,94528599 -2,547965544 0,579052 -4,40024
ENSG00000095015 MAP3K1 44,49573983 -1,601596875 0,366684 -4,36778
ENSG00000280079 CTC-260E6.4 4,201191271 -2,612039681 0,613045 -4,26077
ENSG00000089050 RBBP9 18,85931665 -2,239301793 0,528577 -4,23647
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ENSG00000109501 WFS1 11,45922699 -2,297305349 0,545604 -4,21057
ENSG00000105750 ZNF85 35,18030151 -2,03086483 0,485118 -4,18633
ENSG00000188643 S100A16 658,5606704 -1,602025271 0,386902 -4,14065
ENSG00000050628 PTGER3 22,15704024 -2,396796376 0,57973 -4,13433
ENSG00000113209 PCDHB5 4,603009559 -2,561413963 0,622412 -4,1153
ENSG00000169255 B3GALNT1 6,456259068 -2,420174153 0,5913 -4,09297
ENSG00000138835 RGS3 134,7621143 -1,343148381 0,328301 -4,09121
ENSG00000115461 IGFBP5 43,88760757 -2,456376257 0,607117 -4,04597
ENSG00000167941 SOST 55,5937508 -2,329603289 0,582511 -3,99924
ENSG00000128602 SMO 4,201100881 -2,331501814 0,589037 -3,95816
ENSG00000184220 CMSS1 99,07782163 -1,184435761 0,299615 -3,95319
ENSG00000196814 MVB12B 18,6907974 -2,36958793 0,600272 -3,94753
ENSG00000165259 HDX 3,752930822 -2,416387304 0,615296 -3,92719
ENSG00000137216 TMEM63B 40,97473872 -2,191833358 0,557964 -3,92827
ENSG00000166482 MFAP4 33,74531096 -2,36800861 0,604369 -3,91815
ENSG00000100888 CHD8 120,5148935 -1,370548703 0,35098 -3,90492
ENSG00000198785 GRIN3A 5,057809271 -2,433961659 0,624515 -3,89736
ENSG00000128040 SPINK2 17,31695007 -2,409310609 0,62118 -3,8786
ENSG00000184344 GDF3 47,03429759 -1,608254011 0,414806 -3,87713
ENSG00000172269 DPAGT1 91,17134944 -0,973958418 0,252828 -3,85225
ENSG00000103978 TMEM87A 77,09366437 -0,930827779 0,242655 -3,83602
ENSG00000197859 ADAMTSL2 3,993914273 -2,377353556 0,6191 -3,84001
ENSG00000157152 SYN2 9,446479206 -2,307034408 0,601271 -3,83693
ENSG00000180543 TSPYL5 3,622665339 -2,329868038 0,609108 -3,82505
ENSG00000132622 HSPA12B 7,527287149 -2,359294514 0,618173 -3,81656
ENSG00000154783 FGD5 64,4228883 -1,548935262 0,406995 -3,80578
ENSG00000221923 ZNF880 9,214690052 -2,304807456 0,609095 -3,78399
ENSG00000267383 CTC-260E6.6 3,883965663 -2,232586548 0,592887 -3,76562
ENSG00000120708 TGFBI 91,70684239 -2,076734506 0,551285 -3,76708
ENSG00000278318 ZNF229 6,000326955 -2,312454347 0,614696 -3,76195
ENSG00000182853 VMO1 5,507887137 -2,345260449 0,625084 -3,75191
ENSG00000109099 PMP22 191,524615 -1,714779803 0,458 -3,74406
ENSG00000143621 ILF2 779,2962781 -0,763125525 0,20397 -3,74137
ENSG00000156535 CD109 92,89720586 -1,532077411 0,413633 -3,70395
ENSG00000164053 ATRIP 11,14423421 -1,996586023 0,539181 -3,703
ENSG00000269834 ZNF528-AS1 5,822155471 -2,246975187 0,607714 -3,69742
ENSG00000136869 TLR4 36,50193073 -1,968054924 0,534075 -3,68498
ENSG00000133636 NTS 263,7477271 -1,851710654 0,505231 -3,66508
ENSG00000183072 NKX2-5 7,504153845 -2,287599283 0,624984 -3,66025
ENSG00000171227 TMEM37 64,20801532 -1,828344024 0,501254 -3,64754
ENSG00000118523 CTGF 23,79760678 -2,05484338 0,564356 -3,64104
ENSG00000143878 RHOB 123,0762709 -1,165082318 0,320141 -3,63927
ENSG00000228065 LINC01515 9,063863586 -2,161801995 0,594472 -3,6365
ENSG00000105825 TFPI2 148,9275203 -2,004539393 0,555907 -3,60589
ENSG00000198046 ZNF667 4,673953372 -2,203789836 0,612935 -3,59547
ENSG00000128463 EMC4 243,526124 -1,020257843 0,284652 -3,58422
ENSG00000129219 PLD2 20,75205268 -1,844978284 0,515983 -3,57566
ENSG00000198155 ZNF876P 21,53321141 -1,858631803 0,520801 -3,56879
ENSG00000154864 PIEZO2 10,72154092 -2,04403594 0,574046 -3,56075
ENSG00000188167 TMPPE 8,499811893 -2,171684721 0,610707 -3,55602
ENSG00000167085 PHB 160,4917939 -0,728482562 0,206203 -3,53284
ENSG00000079308 TNS1 15,59828255 -1,907912201 0,542247 -3,51853
ENSG00000173068 BNC2 7,553218219 -2,072085911 0,589584 -3,51449
ENSG00000140937 CDH11 38,05932655 -1,818437228 0,517773 -3,51203
ENSG00000214022 REPIN1 16,34937523 -1,45512511 0,4145 -3,51055
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Downregulated
ENSG00000145623 OSMR 22,88032432 -1,714715805 0,48917 -3,50536
ENSG00000134107 BHLHE40 29,32775574 -1,724282256 0,49275 -3,49931
ENSG00000137959 IFI44L 24,12130347 -2,143875186 0,618601 -3,46569
ENSG00000075336 TIMM21 62,0256047 -1,334155081 0,387092 -3,44661
ENSG00000075213 SEMA3A 4,414059558 -2,148672606 0,624614 -3,44
ENSG00000123411 IKZF4 5,955377563 -2,037072187 0,594437 -3,42689
ENSG00000187123 LYPD6 11,07461616 -2,026908881 0,593353 -3,41602
ENSG00000101955 SRPX 28,49768115 -1,900070277 0,559264 -3,39745
ENSG00000132718 SYT11 7,459581183 -2,085624327 0,614559 -3,39369
ENSG00000116871 MAP7D1 63,43010166 -1,164518143 0,344658 -3,37876
ENSG00000221914 PPP2R2A 127,74934 -1,213673571 0,359423 -3,37673
ENSG00000136111 TBC1D4 91,02589998 -1,505884231 0,447621 -3,3642
ENSG00000260589 STAM-AS1 6,353032422 -2,061083344 0,613598 -3,35901
ENSG00000104883 PEX11G 3,473941597 -2,041500351 0,608034 -3,35755
ENSG00000128656 CHN1 22,22951211 -1,754175298 0,524292 -3,3458
ENSG00000100804 PSMB5 1009,211466 -0,468827604 0,140839 -3,32882
ENSG00000143387 CTSK 20,76828404 -1,906330014 0,573337 -3,32497
ENSG00000161298 ZNF382 15,38563794 -1,959869444 0,590249 -3,32041
ENSG00000197879 MYO1C 52,84678543 -1,454858668 0,43873 -3,31607
ENSG00000088756 ARHGAP28 115,6586262 -1,596855186 0,481915 -3,31356
ENSG00000023734 STRAP 462,0612498 -0,747464329 0,22603 -3,30693
ENSG00000165507 C10orf10 220,6959202 -1,658443129 0,50289 -3,29782
ENSG00000075043 KCNQ2 6,601271751 -2,061423654 0,624991 -3,29832
ENSG00000112414 ADGRG6 36,47477989 -1,745878365 0,529655 -3,29626
ENSG00000077616 NAALAD2 56,93366239 -1,520442973 0,462829 -3,28511
ENSG00000075914 EXOSC7 194,602295 -0,783595705 0,239541 -3,27124
ENSG00000171206 TRIM8 63,84318428 -0,865536936 0,264592 -3,27121
ENSG00000118257 NRP2 283,4681789 -1,532317765 0,469263 -3,26537
ENSG00000143127 ITGA10 10,03941541 -1,785434325 0,547072 -3,26362
ENSG00000023697 DERA 150,4101781 -0,681082172 0,208571 -3,26547
ENSG00000118777 ABCG2 3,843971196 -2,022242023 0,623639 -3,24265
ENSG00000187608 ISG15 184,3901201 -1,394462458 0,429952 -3,24329
ENSG00000126458 RRAS 57,58634609 -1,451973482 0,448239 -3,23928
ENSG00000165449 SLC16A9 16,46524127 -1,890504921 0,585565 -3,22851
ENSG00000184602 SNN 32,10538075 -1,634277643 0,507691 -3,21904
ENSG00000127241 MASP1 23,24454565 -1,845003945 0,576404 -3,20089
ENSG00000149948 HMGA2 90,72469841 -1,52121514 0,475166 -3,20144
ENSG00000114021 NIT2 84,62290275 -1,153181957 0,360509 -3,19876
ENSG00000184384 MAML2 14,57290268 -1,826824148 0,572071 -3,19335
ENSG00000242616 GNG10 6,482908148 -1,554933346 0,488834 -3,1809
ENSG00000148677 ANKRD1 4,28010366 -1,970424552 0,622291 -3,1664
ENSG00000196549 MME 3,945823194 -1,974427338 0,625005 -3,15906
ENSG00000253983 RP1-16A9.1 14,33422465 -1,874651488 0,594221 -3,15481
ENSG00000148516 ZEB1 70,75457064 -1,201599666 0,380806 -3,15541
ENSG00000005448 WDR54 242,8808433 -0,998035849 0,316873 -3,14964
ENSG00000154174 TOMM70A 68,10833425 -1,029143057 0,326615 -3,15094
ENSG00000132256 TRIM5 97,54230397 -1,156660563 0,368004 -3,14307
ENSG00000101230 ISM1 3,50609647 -1,959429369 0,624987 -3,13515
ENSG00000237187 NR2F1-AS1 2,905463012 -1,955399501 0,624047 -3,13342
ENSG00000242193 RP11-568K15.1 3,073799555 -1,950988371 0,623719 -3,12799
ENSG00000130299 GTPBP3 13,910181 -1,466872176 0,471831 -3,1089
ENSG00000154451 GBP5 9,678934476 -1,802622749 0,579799 -3,10905
ENSG00000142065 ZFP14 15,70823406 -1,538362857 0,495279 -3,10605
ENSG00000108352 RAPGEFL1 5,309428532 -1,91989045 0,623119 -3,0811
ENSG00000196611 MMP1 14,43198215 -1,892234278 0,614911 -3,07725
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Downregulated
ENSG00000136546 SCN7A 7,310132654 -1,9043461 0,619072 -3,07613
ENSG00000182983 ZNF662 5,485208999 -1,918878485 0,624159 -3,07434
ENSG00000155438 NIFK 129,0123703 -0,987586753 0,321598 -3,07088
ENSG00000254615 RP11-395G23.3 15,42007794 -1,887702828 0,614815 -3,07036
ENSG00000233056 ERVH48-1 27,2291599 -1,801462596 0,587193 -3,06792
ENSG00000074219 TEAD2 29,84254346 -1,248631404 0,408137 -3,05934
ENSG00000267152 CTD-2528L19.6 4,012936355 -1,884323661 0,617433 -3,05187
ENSG00000197479 PCDHB11 3,421521002 -1,894232329 0,621873 -3,04601
ENSG00000151746 BICD1 67,26482608 -0,959827076 0,314971 -3,04736
ENSG00000254202 RP11-120I21.2 4,008818691 -1,904714553 0,625006 -3,04751
ENSG00000100379 KCTD17 5,170316551 -1,851441418 0,608966 -3,0403
ENSG00000232282 MTND1P32 5,013687738 -1,787125704 0,588479 -3,03686
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Regions differentially enriched in H3K79me3 between double fusion- and MA4/EV-hESC blood derivative.
peak_id peak_start peak_end 7E+05 locus_start locus_end gene_symboloverlap_startoverlap_end
peak:1 21618836 21619430 594 21554783 21719308 ECE1 21618836 21619430
peak:2 27871020 27871960 940 27767914 27873410 WASF2 27871020 27871960
peak:3 41155277 41157219 1942 41144284 41157806 NFYC 41155277 41157219
peak:4 43767794 43768815 1021 43758928 43795178 TIE1 43767794 43768815
peak:5 47695316 47696362 1046 47672771 47723818 TAL1 47695316 47696362
peak:6 52092228 52092904 676 52013924 52263685 OSBPL9 52092228 52092904
peak:7 62226710 62227754 1044 62199623 62549757 PATJ 62226710 62227754
peak:8 91852668 91853280 612 91650423 91918415 HFM1 91852668 91853280
peak:9 92280907 92281736 829 92153990 92393243 TGFBR3 92280907 92281736
peak:10 94703947 94704550 603 94624102 94812278 ARHGAP29 94703947 94704550
peak:11 108502605 108503363 758 108079204 108621488 VAV3 108502605 108503363
peak:12 114481375 114482734 1359 114459956 114514019 HIPK1 114481375 114482734
peak:13 120176292 120176979 687 120166153 120222404 ZNF697 120176292 120176979
peak:14 154463886 154464492 606 154426098 154474610 SHE 154463886 154464492
peak:15 157250423 157251400 977 157103269 157315346 ETV3 157250423 157251400
peak:16 157986113 157987159 1046 157887349 158103061 KIRREL 157986113 157987159
peak:17 163039109 163041536 2427 162938501 163107329 RGS4 163039109 163041536
peak:18 183783701 183785394 1693 183698362 183845013 RGL1 183783701 183785394
peak:19 201510376 201510995 619 201482710 201553241 RPS10P7 201510376 201510995
peak:20 204647245 204647779 534 204574483 204726189 LRRN2 204647245 204647779
peak:21 208383479 208384731 1252 208143618 209009916 PLXNA2 208383479 208384731
peak:22 220703366 220703980 614 220573706 220782598 MARK1 220703366 220703980
peak:23 232629101 232629915 814 232276214 232795940 SIPA1L2 232629101 232629915
peak:24 17932183 17934084 1901 17824513 17935136 SMC6 17932183 17934084
peak:25 28634051 28635122 1071 28417452 28668758 FOSL2 28634051 28635122
peak:26 46534835 46535854 1019 46214208 46656771 EPAS1 46534835 46535854
peak:27 48759327 48760668 1341 48712609 48801122 STON1 48759327 48760668
peak:28 54168333 54168855 522 54100888 54270193 PSME4 54168333 54168855
peak:29 54690992 54692859 1867 54620763 54720378 SPTBN1 54690992 54692859
peak:30 54702819 54703781 962 54620763 54720378 SPTBN1 54702819 54703781
peak:31 72644998 72645642 644 72099974 72714084 CYP26B1 72644998 72645642
peak:32 109229797 109230389 592 109108195 109303602 LIMS1 109229797 109230389
peak:33 109234180 109234886 706 109108195 109303602 LIMS1 109234180 109234886
peak:34 120125114 120125747 633 120124455 120157348 DBI 120125114 120125747
peak:35 121019287 121019855 568 120989313 121057066 RALB 121019287 121019855
peak:36 121029069 121029803 734 120989313 121057066 RALB 121029069 121029803
peak:37 128113068 128113860 792 128076279 128138400 MAP3K2 128113068 128113860
peak:38 133011780 133012292 512 132967090 133015097 MIR663B 133011780 133012292
peak:39 133038386 133038832 446 133015098 133094844 ANKRD30BL 133038386 133038832
peak:40 145187137 145187678 541 145182640 145351746 ZEB2 145187137 145187678
peak:41 145214821 145215668 847 145182640 145351746 ZEB2 145214821 145215668
peak:42 145235431 145235972 541 145182640 145351746 ZEB2 145235431 145235972
peak:43 149902014 149904254 2240 149875716 150060267 LYPD6B 149902014 149904254
peak:44 165598915 165600426 1511 165516586 165755356 COBLL1 165598915 165600426
peak:45 169333032 169334164 1132 169208433 169376106 CERS6 169333032 169334164
peak:46 169337729 169338323 594 169208433 169376106 CERS6 169337729 169338323
peak:47 175525268 175526385 1117 175407155 175588413 WIPF1 175525268 175526385
peak:48 175695012 175695857 845 175670774 175951272 CHN1 175695012 175695857
peak:49 175707639 175708499 860 175670774 175951272 CHN1 175707639 175708499
peak:50 177146909 177147362 453 177093905 177299951 MTX2 177146909 177147362
peak:51 188300740 188301564 824 188013460 188366120 CALCRL 188300740 188301564
peak:52 188303927 188304492 565 188013460 188366120 CALCRL 188303927 188304492
peak:53 188305395 188306865 1470 188013460 188366120 CALCRL 188305395 188306865
peak:54 188308114 188308817 703 188013460 188366120 CALCRL 188308114 188308817
peak:55 188311462 188312080 618 188013460 188366120 CALCRL 188311462 188312080
peak:56 188408262 188409936 1674 188366121 188787807 TFPI 188408262 188409936
peak:57 189838944 189842924 3980 189746966 189840958 COL3A1 189838944 189840958
peak:57 189838944 189842924 3980 189840959 189842852 MIR1245A 189840959 189842852
peak:57 189838944 189842924 3980 189842853 189849641 MIR1245B 189842853 189842924
peak:58 189844676 189851425 6749 189842853 189849641 MIR1245B 189844676 189849641
peak:58 189844676 189851425 6749 189849642 189858375 COL3A1 189849642 189851425
peak:59 190021826 190023085 1259 190021222 190175382 COL5A2 190021826 190023085
peak:60 204395160 204398532 3372 204329741 204485628 RAPH1 204395160 204398532
peak:61 218706287 218706682 395 218650028 218883687 TNS1 218706287 218706682
peak:62 218715866 218716708 842 218650028 218883687 TNS1 218715866 218716708
peak:63 218716730 218719036 2306 218650028 218883687 TNS1 218716730 218719036
peak:64 225815144 225815631 487 225560167 225843518 DOCK10 225815144 225815631
peak:65 238298545 238299318 773 238123121 238358951 COL6A3 238298545 238299318
peak:66 238300753 238301271 518 238123121 238358951 COL6A3 238300753 238301271
peak:67 238304977 238305456 479 238123121 238358951 COL6A3 238304977 238305456
peak:68 238306153 238309255 3102 238123121 238358951 COL6A3 238306153 238309255
peak:69 238621449 238621986 537 238517997 238692545 LRRFIP1 238621449 238621986
peak:70 240135369 240136093 724 240114464 240168743 MGC16025 240135369 240136093
peak:71 240145501 240146534 1033 240114464 240168743 MGC16025 240145501 240146534
peak:72 240149333 240149905 572 240114464 240168743 MGC16025 240149333 240149905
peak:73 240212422 240213123 701 240168744 240223745 HDAC4 240212422 240213123
peak:74 240228231 240229136 905 240223746 240250328 MIR4269 240228231 240229136
peak:75 8554114 8554720 606 8018481 8578480 LMCD1 8554114 8554720
peak:76 8554930 8556174 1244 8018481 8578480 LMCD1 8554930 8556174
peak:77 8556581 8557182 601 8018481 8578480 LMCD1 8556581 8557182
peak:78 8559899 8560829 930 8018481 8578480 LMCD1 8559899 8560829
peak:79 14763030 14763577 547 14708493 14829669 C3orf20 14763030 14763577
peak:80 14853968 14855571 1603 14829670 14956524 FGD5 14853968 14855571
peak:81 17917820 17918600 780 17162158 18125534 TBC1D5 17917820 17918600
peak:82 52085036 52085872 836 52060210 52094794 DUSP7 52085036 52085872
peak:83 55508987 55510075 1088 55238517 55583304 WNT5A 55508987 55510075
peak:84 56795772 56796406 634 56763366 57022484 ARHGEF3 56795772 56796406
peak:85 63842015 63843350 1335 63827320 63849915 THOC7 63842015 63843350
peak:86 69279329 69280973 1644 69210728 69690159 FRMD4B 69279329 69280973
peak:87 73591060 73591723 663 73296906 74122207 PDZRN3 73591060 73591723
peak:88 73599291 73601321 2030 73296906 74122207 PDZRN3 73599291 73601321
peak:89 73641145 73641964 819 73296906 74122207 PDZRN3 73641145 73641964
peak:90 73658671 73660460 1789 73296906 74122207 PDZRN3 73658671 73660460
peak:91 79061908 79062259 351 78178797 80804919 ROBO1 79061908 79062259
peak:92 93710720 93711323 603 93695959 93723218 ARL13B 93710720 93711323
peak:93 149258030 149258652 622 149143969 149283738 TM4SF4 149258030 149258652
peak:94 149301705 149302474 769 149283739 149445700 WWTR1 149301705 149302474
peak:95 149319672 149320175 503 149283739 149445700 WWTR1 149319672 149320175
peak:96 149322137 149323389 1252 149283739 149445700 WWTR1 149322137 149323389
peak:97 149341930 149343051 1121 149283739 149445700 WWTR1 149341930 149343051
peak:98 150464111 150464934 823 150451503 150570405 SIAH2 150464111 150464934
peak:99 150821094 150821835 741 150747119 150862786 MED12L 150821094 150821835
peak:100 152556204 152556776 572 152342734 152716382 P2RY1 152556204 152556776
peak:101 155618589 155619233 644 155580287 155713331 GMPS 155618589 155619233
peak:102 169878401 169879141 740 169827626 169919878 PHC3 169878401 169879141
peak:103 171518375 171518966 591 171285301 171544821 PLD1 171518375 171518966
peak:104 498352 498925 573 492975 556220 PIGG 498352 498925
peak:105 11411842 11412580 738 11400495 12458263 HS3ST1 11411842 11412580
peak:106 16849393 16850772 1379 16649796 17207140 LDB2 16849393 16850772
peak:107 16870346 16871132 786 16649796 17207140 LDB2 16870346 16871132
peak:108 41201940 41202563 623 40805544 41237766 APBB2 41201940 41202563
peak:109 41433689 41434541 852 41310852 41722979 LIMCH1 41433689 41434541
peak:110 46316153 46316998 845 46258740 46651836 GABRA2 46316153 46316998
peak:111 55968864 55970391 1527 55792673 56102075 KDR 55968864 55970391
peak:112 55976377 55977009 632 55792673 56102075 KDR 55976377 55977009
peak:113 56407226 56411318 4092 56288872 56435727 CLOCK 56407226 56411318
peak:114 70296489 70296866 377 70253922 70448546 UGT2B4 70296489 70296866
peak:115 89078604 89079070 466 89013107 89179228 ABCG2 89078604 89079070
peak:116 98336060 98336772 712 97912816 99123459 STPG2 98336060 98336772
peak:117 99503131 99503880 749 99380664 99715027 TSPAN5 99503131 99503880
peak:118 102236712 102237215 503 101932450 102268781 PPP3CA 102236712 102237215
peak:119 106819006 106819440 434 106724284 106992738 NPNT 106819006 106819440
peak:120 111560606 111561890 1284 111470742 112314916 PITX2 111560606 111561890
peak:121 111561918 111563250 1332 111470742 112314916 PITX2 111561918 111563250
peak:122 121989051 121990325 1274 121918844 122039584 NDNF 121989051 121990325
peak:123 140866867 140867382 515 140831078 141126836 MAML3 140866867 140867382
peak:124 170532926 170533631 705 170356299 170537725 NEK1 170532926 170533631
peak:125 171970641 171971262 621 171872974 173412239 GALNTL6 171970641 171971262
peak:126 174451585 174455688 4103 174389030 174828103 HAND2 174451585 174455688
peak:127 174456733 174457313 580 174389030 174828103 HAND2 174456733 174457313
peak:128 177700357 177701207 850 177477493 177972443 VEGFC 177700357 177701207
peak:129 33815995 33816342 347 33666504 33914307 ADAMTS12 33815995 33816342
peak:130 34682324 34683635 1311 34349903 34763466 RAI14 34682324 34683635
peak:131 71146585 71147075 490 70956662 71209054 CARTPT 71146585 71147075
peak:132 75915631 75916611 980 75912092 75944780 F2RL2 75915631 75916611
peak:133 75916941 75919331 2390 75912092 75944780 F2RL2 75916941 75919331
peak:134 76015283 76017317 2034 76010049 76063350 F2R 76015283 76017317
peak:135 82842228 82843032 804 82634807 82900423 VCAN 82842228 82843032
peak:136 82993967 82995862 1895 82900424 83195771 HAPLN1 82993967 82995862
peak:137 83675308 83675942 634 83195772 84629436 EDIL3 83675308 83675942
peak:138 88678070 88678649 579 88050183 88756229 MEF2C 88678070 88678649
peak:139 119438659 119439276 617 119382637 120570241 PRR16 119438659 119439276
peak:140 134371684 134378062 6378 134369468 134528599 PITX1 134371684 134378062
peak:141 134378989 134379580 591 134369468 134528599 PITX1 134378989 134379580
peak:142 134379602 134380282 680 134369468 134528599 PITX1 134379602 134380282
peak:143 134380973 134381561 588 134369468 134528599 PITX1 134380973 134381561
peak:144 138841628 138842123 495 138780040 138852331 ECSCR 138841628 138842123
peak:145 149531548 149532482 934 149504776 149540883 PDGFRB 149531548 149532482
peak:146 153628730 153629524 794 153494408 153751441 GALNT10 153628730 153629524
peak:147 168710264 168710743 479 168709416 168869385 SLIT3 168710264 168710743
peak:148 168720216 168724104 3888 168709416 168869385 SLIT3 168720216 168724104
peak:149 171607930 171608476 546 171524612 171618261 STK10 171607930 171608476
peak:150 173321859 173322378 519 173179499 173386363 CPEB4 173321859 173322378
peak:151 178013980 178014644 664 177678584 178035805 COL23A1 178013980 178014644
peak:152 179767625 179769376 1751 179749694 179850866 GFPT2 179767625 179769376
peak:153 24904932 24905894 962 24826613 25090224 FAM65B 24904932 24905894
peak:154 33789984 33790510 526 33764350 33816160 MLN 33789984 33790510
peak:155 41906137 41906900 763 41899055 42017430 CCND3 41906137 41906900
peak:156 43069195 43070889 1694 43036095 43119539 PTK7 43069195 43070889
peak:157 44670589 44671034 445 44379315 44738564 MIR4642 44670589 44671034
peak:158 44671581 44672269 688 44379315 44738564 MIR4642 44671581 44672269
peak:159 86163397 86164057 660 85816629 86218751 NT5E 86163397 86164057
peak:160 91226084 91226619 535 91134700 91764199 MAP3K7 91226084 91226619
peak:161 98343495 98344020 525 98167346 98877493 MIR2113 98343495 98344020
peak:162 138809524 138810570 1046 138788506 138953236 NHSL1 138809524 138810570
peak:163 147531349 147531922 573 147526429 147737961 STXBP5 147531349 147531922
peak:164 157262218 157262772 554 157178733 157500926 ARID1B 157262218 157262772
peak:165 6052643 6053433 790 6048810 6059944 AIMP2 6052643 6053433
peak:166 22258202 22258490 288 22093851 22468217 RAPGEF5 22258202 22258490
peak:167 26074531 26075475 944 25935119 26090726 MIR148A 26074531 26075475
peak:168 27202934 27209614 6680 27200723 27207165 HOXA9 27202934 27207165
peak:168 27202934 27209614 6680 27207166 27211568 MIR196B 27207166 27209614
peak:169 27210826 27219500 8674 27207166 27211568 MIR196B 27210826 27211568
peak:169 27210826 27219500 8674 27211569 27222357 HOXA10 27211569 27219500
peak:170 27232641 27233483 842 27232284 27239882 HOXA13 27232641 27233483
peak:171 27234692 27235912 1220 27232284 27239882 HOXA13 27234692 27235912
peak:172 27281139 27284013 2874 27261103 27485780 EVX1 27281139 27284013
peak:173 27811436 27811765 329 27740807 27905694 TAX1BP1 27811436 27811765
peak:174 29700851 29701893 1042 29661936 29722607 MIR550A3 29700851 29701893
peak:175 29702454 29703401 947 29661936 29722607 MIR550A3 29702454 29703401
peak:176 29716072 29717020 948 29661936 29722607 MIR550A3 29716072 29717020
peak:177 29717084 29718133 1049 29661936 29722607 MIR550A3 29717084 29718133
peak:178 30960869 30961483 614 30924392 30982377 AQP1 30960869 30961483
peak:179 32328879 32329394 515 31918549 32434203 PDE1C 32328879 32329394
peak:180 33958414 33958857 443 33667270 34321210 BMPER 33958414 33958857
peak:181 35284954 35285617 663 35259743 35514228 TBX20 35284954 35285617
peak:182 43695681 43696256 575 43406594 43695916 STK17A 43695681 43695916
peak:182 43695681 43696256 575 43695917 43783706 COA1 43695917 43696256
peak:183 79765871 79770957 5086 79582357 79881981 GNAI1 79765871 79770957
peak:184 94029143 94029692 549 93828782 94093103 COL1A2 94029143 94029692
peak:185 97950456 97951212 756 97896272 97970703 BRI3 97950456 97951212
peak:186 1780828 1781459 631 1768774 1876422 ARHGEF10 1780828 1781459
peak:187 10582724 10583330 606 10559085 10635487 SOX7 10582724 10583330
peak:188 20038777 20039619 842 19918650 20047710 SLC18A1 20038777 20039619
peak:189 37669114 37669986 872 37637252 37680916 ADGRA2 37669114 37669986
peak:190 37670156 37670966 810 37637252 37680916 ADGRA2 37670156 37670966
peak:191 37897298 37898459 1161 37856103 37925515 EIF4EBP1 37897298 37898459
peak:192 48864485 48865178 693 48761735 48872753 PRKDC 48864485 48865178
peak:193 49295108 49296034 926 49284433 49740934 EFCAB1 49295108 49296034
peak:194 49828980 49834100 5120 49740935 49900447 SNAI2 49828980 49834100
peak:195 58969532 58970281 749 58549608 59115468 FAM110B 58969532 58970281
peak:196 79428973 79429516 543 78670809 79540874 PKIA 79428973 79429516
peak:197 93033549 93034137 588 92632817 93456871 RUNX1T1 93033549 93034137
peak:198 95445551 95448329 2778 95361864 95513467 RAD54B 95445551 95448329
peak:199 102524986 102525522 536 102442895 102654053 GRHL2 102524986 102525522
peak:200 102546839 102547518 679 102442895 102654053 GRHL2 102546839 102547518
peak:201 106337054 106338228 1174 105966200 106992762 ZFPM2 106337054 106338228
peak:202 106338309 106340334 2025 105966200 106992762 ZFPM2 106338309 106340334
peak:203 106340804 106341562 758 105966200 106992762 ZFPM2 106340804 106341562
peak:204 106374855 106375487 632 105966200 106992762 ZFPM2 106374855 106375487
peak:205 106380509 106381181 672 105966200 106992762 ZFPM2 106380509 106381181
peak:206 106381391 106382004 613 105966200 106992762 ZFPM2 106381391 106382004
peak:207 106413579 106414280 701 105966200 106992762 ZFPM2 106413579 106414280
peak:208 124169312 124169710 398 124164792 124211184 FAM83A 124169312 124169710
peak:209 144771302 144772218 916 144749289 144772953 ZNF707 144771302 144772218
peak:210 16484326 16485027 701 16356917 17002912 BNC2 16484326 16485027
peak:211 16789404 16790188 784 16356917 17002912 BNC2 16789404 16790188
peak:212 16828950 16832075 3125 16356917 17002912 BNC2 16828950 16832075
peak:213 16832166 16832985 819 16356917 17002912 BNC2 16832166 16832985
peak:214 16833064 16835139 2075 16356917 17002912 BNC2 16833064 16835139
peak:215 16835678 16838916 3238 16356917 17002912 BNC2 16835678 16838916
peak:216 16841587 16845686 4099 16356917 17002912 BNC2 16841587 16845686
peak:217 16850699 16852788 2089 16356917 17002912 BNC2 16850699 16852788
peak:218 16853303 16855571 2268 16356917 17002912 BNC2 16853303 16855571
peak:219 16855770 16857548 1778 16356917 17002912 BNC2 16855770 16857548
peak:220 16864908 16866306 1398 16356917 17002912 BNC2 16864908 16866306
peak:221 18549881 18550727 846 18523692 18699720 MIR3152 18549881 18550727
peak:222 20693805 20694368 563 20687207 20768198 MIR491 20693805 20694368
peak:223 27126520 27127273 753 27057420 27220305 TEK 27126520 27127273
peak:224 27142964 27143524 560 27057420 27220305 TEK 27142964 27143524
peak:225 34116427 34117310 883 34087860 34152887 DCAF12 34116427 34117310
peak:226 37992368 37992931 563 37986781 38230935 SHB 37992368 37992931
peak:227 108027552 108028747 1195 107848729 108164036 SLC44A1 108027552 108028747
peak:228 108031856 108032804 948 107848729 108164036 SLC44A1 108031856 108032804
peak:229 111650827 111651505 678 111639663 111696640 IKBKAP 111650827 111651505
peak:230 112547947 112548821 874 112331831 112676727 PALM2 112547947 112548821
peak:231 124128773 124129673 900 124103166 124197444 STOM 124128773 124129673
peak:232 125796359 125797211 852 125749611 125836839 GPR21 125796359 125797211
peak:233 125800184 125800852 668 125749611 125836839 GPR21 125800184 125800852
peak:234 126129800 126131502 1702 126074652 126141665 CRB2 126129800 126131502
peak:235 130317788 130318293 505 130294416 130357877 FAM129B 130317788 130318293
peak:236 134147587 134148770 1183 134106696 134158493 FAM78A 134147587 134148770
peak:237 134149070 134152060 2990 134106696 134158493 FAM78A 134149070 134152060
peak:238 137616525 137617372 847 137421328 137637433 COL5A1 137616525 137617372
peak:239 138973618 138974226 608 138920179 138998704 NACC2 138973618 138974226
peak:240 139423069 139424634 1565 139411041 139427158 MIR4673 139423069 139424634
peak:241 1093416 1094782 1366 1081438 1095269 IDI1 1093416 1094782
peak:242 6144391 6145180 789 6117642 6171484 RBM17 6144391 6145180
peak:243 24633820 24634513 693 24554436 24651604 MIR603 24633820 24634513
peak:244 29946523 29947035 512 29907589 30187176 SVIL 29946523 29947035
peak:245 30329105 30330584 1479 30187177 30521343 KIAA1462 30329105 30330584
peak:246 33602986 33604361 1375 33435531 33842807 NRP1 33602986 33604361
peak:247 33612310 33623591 11281 33435531 33842807 NRP1 33612310 33623591
peak:248 69524126 69524508 382 69055605 69526943 CTNNA3 69524126 69524508
peak:249 71563416 71564435 1019 71475824 71687000 COL13A1 71563416 71564435
peak:250 72972242 72977264 5022 72810417 73025651 UNC5B 72972242 72977264
peak:251 80947229 80947935 706 80828665 81086538 ZMIZ1 80947229 80947935
peak:252 88716692 88717151 459 88616911 88717856 MMRN2 88716692 88717151
peak:253 91155250 91155882 632 91145059 91163314 IFIT1 91155250 91155882
peak:254 104552485 104553797 1312 104489013 104566589 WBP1L 104552485 104553797
peak:255 104559723 104560312 589 104489013 104566589 WBP1L 104559723 104560312
peak:256 112837909 112838721 812 112780337 113390129 ADRA2A 112837909 112838721
peak:257 116158426 116160362 1936 116034844 116208076 AFAP1L2 116158426 116160362
peak:258 123244575 123245599 1024 122927677 123522759 FGFR2 123244575 123245599
peak:259 130381649 130382040 391 129885908 130594961 MKI67 130381649 130382040
peak:260 2017705 2019003 1298 1993282 2018563 MIR675 2017705 2018563
peak:260 2017705 2019003 1298 2018564 2087252 H19 2018564 2019003
peak:261 2160943 2164498 3555 2156971 2176525 IGF2 2160943 2164498
peak:262 11268043 11268592 549 11127263 11509232 CSNK2A3 11268043 11268592
peak:263 12402647 12403252 605 12353737 12557878 PARVA 12402647 12403252
peak:264 12404587 12407120 2533 12353737 12557878 PARVA 12404587 12407120
peak:265 12410514 12411161 647 12353737 12557878 PARVA 12410514 12411161
peak:266 12414622 12416345 1723 12353737 12557878 PARVA 12414622 12416345
peak:267 12834669 12835287 618 12557879 12956175 TEAD1 12834669 12835287
peak:268 16566539 16567254 715 15797531 16694225 SOX6 16566539 16567254
peak:269 16592793 16593551 758 15797531 16694225 SOX6 16592793 16593551
peak:270 16609429 16610177 748 15797531 16694225 SOX6 16609429 16610177
peak:271 16615703 16616149 446 15797531 16694225 SOX6 16615703 16616149
peak:272 16623340 16624503 1163 15797531 16694225 SOX6 16623340 16624503
peak:273 27433611 27434180 569 27230870 27439564 CCDC34 27433611 27434180
peak:274 44798075 44798691 616 44686559 44949858 TSPAN18 44798075 44798691
peak:275 46377734 46378238 504 46345834 46390548 DGKZ 46377734 46378238
peak:276 48050352 48050895 543 47936084 48197802 PTPRJ 48050352 48050895
peak:277 61534047 61535299 1252 61523999 61535107 DKFZP434K02861534047 61535107
peak:277 61534047 61535299 1252 61535108 61552555 MYRF 61535108 61535299
peak:278 66486509 66487328 819 66450413 66500538 SPTBN2 66486509 66487328
peak:279 66493674 66495379 1705 66450413 66500538 SPTBN2 66493674 66495379
peak:280 82581850 82582560 710 82528232 82612147 PRCP 82581850 82582560
peak:281 82583067 82583651 584 82528232 82612147 PRCP 82583067 82583651
peak:282 85194858 85195323 465 83195442 85338965 DLG2 85194858 85195323
peak:283 114316541 114317397 856 114290747 114355869 REXO2 114316541 114317397
peak:284 121332485 121333650 1165 121243245 121715840 SORL1 121332485 121333650
peak:285 128361238 128362192 954 127632781 128506941 ETS1 128361238 128362192
peak:286 128600867 128601738 871 128596965 128670219 FLI1 128600867 128601738
peak:287 129984417 129985076 659 129906224 130019573 APLP2 129984417 129985076
peak:288 133953655 133955119 1464 133882735 134016623 JAM3 133953655 133955119
peak:289 133956162 133956636 474 133882735 134016623 JAM3 133956162 133956636
peak:290 11830639 11831672 1033 11751877 12123118 ETV6 11830639 11831672
peak:291 20704229 20704633 404 20057848 20786543 PDE3A 20704229 20704633
peak:292 33592073 33592479 406 33321268 33883985 SYT10 33592073 33592479
peak:293 34372437 34372829 392 33883986 36442886 ALG10 34372437 34372829
peak:294 47468861 47473585 4724 47346584 47473560 PCED1B 47468861 47473560
peak:294 47468861 47473585 4724 47473561 47527664 AMIGO2 47473561 47473585
peak:295 48578048 48580774 2726 48564372 48587220 CCDC184 48578048 48580774
peak:296 48581132 48581632 500 48564372 48587220 CCDC184 48581132 48581632
peak:297 48740759 48744225 3466 48733719 48805738 ZNF641 48740759 48744225
peak:298 50095140 50096362 1222 50035177 50118245 FMNL3 50095140 50096362
peak:299 51319023 51320625 1602 51277618 51333292 METTL7A 51319023 51320625
peak:300 54411997 54412633 636 54406767 54424513 HOXC6 54411997 54412633
peak:301 54422385 54422911 526 54406767 54424513 HOXC6 54422385 54422911
peak:302 54520010 54522014 2004 54517390 54604019 SMUG1 54520010 54522014
peak:303 54526117 54526871 754 54517390 54604019 SMUG1 54526117 54526871
peak:304 62661805 62662398 593 62654024 62757359 USP15 62661805 62662398
peak:305 76945776 76946352 576 76779548 77055721 OSBPL8 76945776 76946352
peak:306 91497059 91498160 1101 91478837 91538952 LUM 91497059 91498160
peak:307 91566883 91567833 950 91538953 92056147 DCN 91566883 91567833
peak:308 91572618 91573569 951 91538953 92056147 DCN 91572618 91573569
peak:309 95535046 95536009 963 95499430 95611381 FGD6 95535046 95536009
peak:310 95539092 95539807 715 95499430 95611381 FGD6 95539092 95539807
peak:311 96423196 96423846 650 96399548 96512752 LTA4H 96423196 96423846
peak:312 96601230 96602388 1158 96512753 96691286 ELK3 96601230 96602388
peak:313 109227249 109229598 2349 109162144 109252033 SSH1 109227249 109229598
peak:314 111855696 111856834 1138 111825339 111890655 SH2B3 111855696 111856834
peak:315 111860717 111861162 445 111825339 111890655 SH2B3 111860717 111861162
peak:316 116460997 116461510 513 115854215 116650725 MIR620 116460997 116461510
peak:317 116462513 116463600 1087 115854215 116650725 MIR620 116462513 116463600
peak:318 116465234 116466269 1035 115854215 116650725 MIR620 116465234 116466269
peak:319 116466391 116469400 3009 115854215 116650725 MIR620 116466391 116469400
peak:320 116476688 116479586 2898 115854215 116650725 MIR620 116476688 116479586
peak:321 29052854 29053736 882 28815491 29151203 FLT1 29052854 29053736
peak:322 70834842 70835388 546 70681986 71135949 KLHL1 70834842 70835388
peak:323 97886176 97888570 2394 97720348 98042885 MBNL2 97886176 97888570
peak:324 97888978 97890385 1407 97720348 98042885 MBNL2 97888978 97890385
peak:325 113424650 113425196 546 113323001 113559702 ATP11A 113424650 113425196
peak:326 114844483 114845177 694 114716817 114949228 RASA3 114844483 114845177
peak:327 114862352 114862769 417 114716817 114949228 RASA3 114862352 114862769
peak:328 114874693 114876466 1773 114716817 114949228 RASA3 114874693 114876466
peak:329 114878447 114879160 713 114716817 114949228 RASA3 114878447 114879160
peak:330 27858359 27859154 795 27729822 28659036 LINC00645 27858359 27859154
peak:331 52513146 52521420 8274 52496088 52635188 NID2 52513146 52521420
peak:332 64966283 64967079 796 64951386 64970628 ZBTB25 64966283 64967079
peak:333 65194298 65196221 1923 65112010 65227024 PLEKHG3 65194298 65196221
peak:334 75745948 75747572 1624 75694416 75753726 FOS 75745948 75747572
peak:335 75911206 75912346 1140 75827809 75943810 JDP2 75911206 75912346
peak:336 41225335 41225921 586 41204080 41233583 DLL4 41225335 41225921
peak:337 50400402 50401262 860 50040977 50442906 ATP8B4 50400402 50401262
peak:338 53827799 53828339 540 53457630 54180088 WDR72 53827799 53828339
peak:339 55255684 55256393 709 55195386 55525856 RSL24D1 55255684 55256393
peak:340 57680561 57685031 4470 57630634 57776402 CGNL1 57680561 57685031
peak:341 60661001 60661414 413 60493304 60718084 ANXA2 60661001 60661414
peak:342 68132224 68132783 559 68022467 68229307 SKOR1 68132224 68132783
peak:343 78361246 78361773 527 78149052 78372934 TBC1D2B 78361246 78361773
peak:344 83939486 83940588 1102 83914419 84034779 BNC1 83939486 83940588
peak:345 23137116 23137663 547 22954865 23177315 USP31 23137116 23137663
peak:346 33962904 33963356 452 33612312 34183632 LINC00273 33962904 33963356
peak:347 65122252 65122769 517 63554842 65276815 CDH11 65122252 65122769
peak:348 65275625 65276174 549 63554842 65276815 CDH11 65275625 65276174
peak:349 65280051 65280935 884 65276816 66005364 LINC00922 65280051 65280935
peak:350 67499011 67499644 633 67479083 67516402 ATP6V0D1 67499011 67499644
peak:351 68706305 68706780 475 68625907 68724673 CDH3 68706305 68706780
peak:352 75489293 75490494 1201 75482851 75513755 TMEM170A 75489293 75490494
peak:353 77465736 77467040 1304 77321978 77612700 ADAMTS18 77465736 77467040
peak:354 84865362 84867141 1779 84793572 84949364 CRISPLD2 84865362 84867141
peak:355 84867188 84868387 1199 84793572 84949364 CRISPLD2 84867188 84868387
peak:356 86537415 86539157 1742 86460876 86543299 FENDRR 86537415 86539157
peak:357 86539384 86541739 2355 86460876 86543299 FENDRR 86539384 86541739
peak:358 86544002 86551528 7526 86543300 86566243 FOXF1 86544002 86551528
peak:359 4411509 4412371 862 4369675 4442887 SPNS2 4411509 4412371
peak:360 4412486 4413888 1402 4369675 4442887 SPNS2 4412486 4413888
peak:361 7611015 7611676 661 7606290 7614799 EFNB3 7611015 7611676
peak:362 15146073 15146631 558 15044653 15159553 MIR4731 15146073 15146631
peak:363 15152152 15152660 508 15044653 15159553 MIR4731 15152152 15152660
peak:364 15154738 15155824 1086 15044653 15159553 MIR4731 15154738 15155824
peak:365 15156973 15157873 900 15044653 15159553 MIR4731 15156973 15157873
peak:366 15161580 15163773 2193 15159554 15206801 PMP22 15161580 15163773
peak:367 20783982 20784869 887 20641246 20872902 CCDC144NL 20783982 20784869
peak:368 25850578 25851670 1092 25772034 25947557 KSR1 25850578 25851670
peak:369 28457021 28457549 528 28444138 28463722 MIR3184 28457021 28457549
peak:370 29907826 29908340 514 29902360 30044378 MIR365B 29907826 29908340
peak:371 36610107 36610693 586 36546364 36669058 ARHGAP23 36610107 36610693
peak:372 36613351 36614272 921 36546364 36669058 ARHGAP23 36613351 36614272
peak:373 40513617 40514505 888 40499324 40557893 STAT3 40513617 40514505
peak:374 46641880 46654040 12160 46626315 46654090 HOXB3 46641880 46654040
peak:375 46655944 46662212 6268 46654091 46656526 HOXB4 46655944 46656526
peak:375 46655944 46662212 6268 46656527 46658562 MIR10A 46656527 46658562
peak:375 46655944 46662212 6268 46658563 46669367 HOXB3 46658563 46662212
peak:376 46662319 46671164 8845 46658563 46669367 HOXB3 46662319 46669367
peak:376 46662319 46671164 8845 46669368 46676718 HOXB5 46669368 46671164
peak:377 46671218 46685602 14384 46669368 46676718 HOXB5 46671218 46676718
peak:377 46671218 46685602 14384 46676719 46685368 HOXB6 46676719 46685368
peak:377 46671218 46685602 14384 46685369 46690342 HOXB7 46685369 46685602
peak:378 46698382 46701475 3093 46698069 46706878 HOXB9 46698382 46701475
peak:379 46701835 46703183 1348 46698069 46706878 HOXB9 46701835 46703183
peak:380 48134857 48135604 747 48102965 48152720 ITGA3 48134857 48135604
peak:381 60727017 60728343 1326 60631619 60821415 MRC2 60727017 60728343
peak:382 62610344 62610838 494 62593672 62738303 SMURF2 62610344 62610838
peak:383 72425330 72425990 660 72395657 72450873 GPRC5C 72425330 72425990
peak:384 73677273 73677974 701 73663335 73690457 SAP30BP 73677273 73677974
peak:385 78526234 78527056 822 78484515 78944438 RPTOR 78526234 78527056
peak:386 81042045 81046708 4663 81023627 81108307 METRNL 81042045 81046708
peak:387 6730641 6740773 10132 6649955 6889670 ARHGAP28 6730641 6740773
peak:388 6773975 6775515 1540 6649955 6889670 ARHGAP28 6773975 6775515
peak:389 43771278 43772276 998 43719144 43830380 C18orf25 43771278 43772276
peak:390 53058240 53058853 613 52798296 53138910 TCF4 53058240 53058853
peak:391 11207061 11208924 1863 11165648 11252584 LDLR 11207061 11208924
peak:392 17483803 17484462 659 17468232 17502260 PLVAP 17483803 17484462
peak:393 17486542 17487410 868 17468232 17502260 PLVAP 17486542 17487410
peak:394 24183657 24183873 216 24156966 24308112 ZNF254 24183657 24183873
peak:395 31775147 31775723 576 31740487 31959642 TSHZ3 31775147 31775723
peak:396 31808196 31809598 1402 31740487 31959642 TSHZ3 31808196 31809598
peak:397 31841439 31843763 2324 31740487 31959642 TSHZ3 31841439 31843763
peak:398 31845066 31845687 621 31740487 31959642 TSHZ3 31845066 31845687
peak:399 36066328 36066921 593 36042626 36079103 ATP4A 36066328 36066921
peak:400 54376620 54378204 1584 54348635 54379124 MYADM 54376620 54378204
peak:401 55542916 55543440 524 55513672 55557464 GP6 55542916 55543440
peak:402 587634 588435 801 557697 612462 TCF15 587634 588435
peak:403 17614207 17615256 1049 17588903 17668624 RRBP1 17614207 17615256
peak:404 19969145 19969984 839 19956839 20015798 NAA20 19969145 19969984
peak:405 23026698 23028411 1713 23023180 23048639 THBD 23026698 23028411
peak:406 48599528 48604817 5289 48576214 48628839 SNAI1 48599528 48604817
peak:407 49275133 49275912 779 49227875 49327998 FAM65C 49275133 49275912
peak:408 49304551 49305860 1309 49227875 49327998 FAM65C 49304551 49305860
peak:409 50155602 50155980 378 50114387 50246706 NFATC2 50155602 50155980
peak:410 57464269 57466116 1847 57404082 57517149 GNAS 57464269 57466116
peak:411 9826877 9827690 813 9826018 9897398 MIR3687-1 9826877 9827690
peak:412 15910563 15911212 649 15837096 16196424 SAMSN1 15910563 15911212
peak:413 28211847 28217731 5884 28081655 28272004 ADAMTS1 28211847 28217731
peak:414 29466657 29467408 751 29240191 29648661 LINC00314 29466657 29467408
peak:415 33739292 33739898 606 33718237 33775032 URB1 33739292 33739898
peak:416 38626544 38627209 665 38610319 38689846 DSCR3 38626544 38627209
peak:417 39868629 39869645 1016 39709987 40078942 ERG 39868629 39869645
peak:418 44400848 44402672 1824 44354011 44456475 PKNOX1 44400848 44402672
peak:419 46203226 46203991 765 46176624 46229897 UBE2G2 46203226 46203991
peak:420 46700079 46700967 888 46634925 46766454 POFUT2 46700079 46700967
peak:421 47401672 47407366 5694 47358893 47469572 COL6A1 47401672 47407366
peak:422 47516950 47517447 497 47469573 47540344 COL6A2 47516950 47517447
peak:423 47518597 47531485 12888 47469573 47540344 COL6A2 47518597 47531485
peak:424 47531878 47535394 3516 47469573 47540344 COL6A2 47531878 47535394
peak:425 20788478 20789449 971 20770276 20821158 SCARF2 20788478 20789449
peak:426 26952565 26953742 1177 26929864 26956329 MIR548J 26952565 26953742
peak:427 26975135 26975847 712 26956330 27000040 TPST2 26975135 26975847
peak:428 31647411 31648425 1014 31582195 31665530 LIMK2 31647411 31648425
peak:429 31650134 31650700 566 31582195 31665530 LIMK2 31650134 31650700
peak:430 39873686 39874512 826 39824543 39889667 MGAT3 39873686 39874512
peak:431 41208671 41209275 604 41142620 41212677 MIR4766 41208671 41209275
peak:432 50952415 50953010 595 50946391 50955339 NCAPH2 50952415 50953010
peak:433 45656406 45657062 656 45606113 45956577 MIR222 45656406 45657062
peak:434 64927214 64928223 1009 64829907 65068474 MSN 64927214 64928223
peak:435 131169422 131170423 1001 131060959 131192913 STK26 131169422 131170423
Regions differentially enriched in H3K79me3 between double fusion- and MA4/EV-hESC blood derivative.
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